Taysha Gene Therapies, Inc. (TSHA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the Tatia Gene Therapy's first quarter 2025 earnings call. At this time, all participants are in listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star then zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Haley Collins, Director, Head of Corporate Communications. Please go ahead. Thank you. Good morning and welcome to Tayshia's first quarter 2025 financial results and corporate update conference call. Earlier today, Tayshia issued a press release announcing financial results for the first quarter ended March 31st, 2025. A copy of this press release is available on the company's website and through our SEC filing. Joining me on today's call are Sean Nolan, Cassius Chief Executive Officer, Sigmar Nagandran, President and Head of R&D, and Cameron Alam, Chief Financial Officer. We will hold a question and answer session following our prepared remarks. Please note that on today's call, we will be making forward-looking statements 102, including the reproducibility and durability of any favorable results initially seen in the patient's dose to date in clinical trials to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development, and regulatory plans for our product candidates, including the timing of additional trials and reporting data from our clinical trials, advice from the FDA on the regulatory pathway for TASHA 102, the potential for the product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, the market opportunity for o...